CCL2 and neoplasm: Having shown that enavatuzumab treatment of tumor cells stimulated release of multiple cytokines and chemokines in vitro and that MCP-1 appeared to be a key functional chemokine in immune cell migration, we next tested whether enavatuzumab stimulated release of MCP-1 in vivo.